Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19.
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome.
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control.
Altered T-cell subset distribution in the viral reservoir in HIV-1-infected individuals with extremely low proviral DNA.
Considerations for successful therapeutic immunization in HIV cure.
Incoming HIV virion-derivedGag Spacer Peptide 2 (p1) is a targetof effective CD8+T cell antiviral responses
Absence of drug-drug interactions between γ-hydroxybutyric acid (GHB) and cobicistat.
Effects of integrase inhibitor-based antiretroviral therapy on brain outcomes according to time since acquisition of HIV-1 infection.
Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy.
TL1A-DR3 Plasma Levels Are Predictive of HIV-1 Disease Control, and DR3 Costimulation Boosts HIV-1-Specific T Cell Responses.